Evidence map›Paper›PMID 38098630›Full record

ArticleFrontiers in psychiatry2023

Significant gender-specific difference in brain lateralization of schizophrenia patients assessed by new combined foot dominance scale.

Katerina Akabalieva

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Katerina AkabalievaDepartment of Apasychiatry and Amaedical Apasychology, Faculty of Medicine, Medical University Sofia, Sofia, Bulgaria.
Medical University of Sofia · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Reduced hemispheric asymmetry has been identified as a potential risk factor for schizophrenia, characterized by diminished brain lateralization and a lack of dominance in the left hemisphere. Moreover, there is growing evidence of disrupted connectivity between various cortical regions. This study aimed to investigate gender differences in left-footedness as a potential biological marker for neuronal dysontogenesis in individuals with schizophrenia and control subjects. Materials and methods: A New Combined Foot Dominance Scale (14 foot tests), comprising a Modified Chapman & Chapman Subscale (10 foot tests) and a Complex Tasks Subscale (four foot tests) was administered as performance tasks in 180 subjects [98 schizophrenia patients with mean age 34.45 years (SD = 15.67, range 23-79) for men and 42.20 years (SD = 11.38, range 21-63) for women and 82 controls with a mean age 34.70 years (SD = 16,82, range 18-79) for men and 44.50 years (SD = 10.73, range 23-67)]. As our data are not continuous and lacks normal distribution, the non-parametric Mann-Whitney test was used for comparing categorical data. Results: The mean left-footedness, as assessed by the New Combined Foot Dominance Scale, is significantly higher in individuals with schizophrenia compared to control subjects. Our findings from inter-gender comparisons reveal that female schizophrenia patients exhibit a significantly greater average left-footedness than female control subjects, while in males no such a statistical significant difference is detected. Conclusion: Left foot dominance is higher in patients with schizophrenia than in control subjects and women contribute significantly more to this difference.

Indexed as

biological markerdysontogenesisfoot dominancegender dimorphismlateralityschizophrenia

Identifiers

PMID38098630
PMCPMC10719836
OpenAlexW4389203301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.